I-CD20, Columbi, I-DLBCL, I-Genentech
I-Glofitamab-gxbm igunyazwe yi-FDA kuma-B-cell lymphomas akhethiwe abuyele emuva noma aphikisayo.
July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell ly..
I-B-cell lymphoma, I-DLBCL, I-POLARIX, I-Polatuzumab, i-polatuzumab vedotin
I-Polatuzumab vedotin-piiq igunyazwe yi-USFDA ngokusabalalisa i-B-cell lymphoma enkulu, okungashiwongo ngenye indlela, kanye ne-high-grade B-cell lymphoma.
Meyi 2023: Ezigulini ezikhulile ezinezinga eliphezulu le-B-cell lymphoma (HGBL), engacacisiwe ngenye indlela (NOS), noma ezisabalalisa i-B-cell lymphoma (DLBCL) enkulu ezingakaze zithole ukwelashwa futhi ezine-International Prognostic Inde.
Ukwelashwa kwe-CAR - T Cell, Inkampani CARsgen Therapeutics Co, Inkampani kaDaiichi Sankyo, I-DLBCL, Ucwaningo lwe-Emergen, Limited, I-Novartis AG
Imakethe ye-CAR T-Cell therapy izokhula ngezinga elimangalisayo eminyakeni eyi-8 ezayo
NgoJulayi 2022: Ngokocwaningo lwakamuva olwenziwe yi-Emergen Research, imakethe yomhlaba wonke yokwelashwa ngamaseli e-CAR T ifinyelele kusayizi we-USD 1.29 billion ngo-2021 futhi kulindeleke ukuthi ibhalise i-CAGR yemali engenayo yamaphesenti angama-24.9 ..
I-Burkitt lymphoma, I-Burkitt-like lymphoma, I-DLBCL, I-Genentech, I-Rituxan, I-Rituximab
I-Rituximab plus chemotherapy igunyazwe yi-FDA ngezinkomba zomdlavuza wezingane
Mashi 2022: I-Food and Drug Administration igunyaze i-rituximab (Rituxan, Genentech, Inc.) ngokuhlanganyela ne-chemotherapy ye-CD20-positive diffuse big-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma.
I-ADC Therapeutics SA, i-alkylating agent conjugate, I-antibody eqondiswe ku-CD19, ububanzi bokusabalalisa i-B-cell lymphoma, I-DLBCL, izinga eliphezulu le-B-cell lymphoma, I-B-cell lymphoma enkulu, ILoncastuximab tesirine-lpyl, Zynlonta
I-FDA inikeze imvume esheshayo ye-loncastuximab tesirine-lpyl ye-B-cell lymphoma enkulu
Agasti 2021: I-FDA inikeze i-loncastuximab tesirine-lpyl (i-Zynlonta, i-ADC Therapeutics SA), i-CD19 eqondiswe ku-antibody kanye ne-alkylating agent conjugate, evumela ukusheshiswa kweziguli ezindala ezine-B-cell enkulu ebuyile noma ephikisayo ..
I-DLBCL, IHodgkin lymphoma, i-lymphoma, NHL, I-Non Hodgkin lymphoma
Kungani abantu abasha benesifo esiphakeme se-lymphoma?
I-LymphAbantu banolwazi oluncane kakhulu lwe-lymph. Intamo, i-groin, namakhwapha konke kuyi-lymph. Uma kunenkinga ngohlelo lwe-lymphatic, ubuthi bomzimba buzogcinwa ngobuningi obukhulu, futhi i-lymphoma maduze nje.